lower (study A) or between 7.5% and 11% (study B) at screening. Fasting blood glucose was to be less than 14.4 mmol/liter (study A) or less than13.3 mmol/liter (study B) before starting the study. All subjects providedwritten informed consent before participation in these studies, whichwere approved by an institutional review board (University of NorthCarolina, Durham, NC) and conducted in accordance with the principlesendorsed by the Declaration of Helsinki. Study design Study A: postprandial evaluations. This single-blind, placebo-controlled, two-period crossover study was designed to evaluate the effects of 0.1 /H9262g/kg AC2993 administered sc twice daily (BID), immediately before